ArticleDiscover oncology2025
Prognostic value of FCER1G expression and M2 macrophage infiltration in esophageal squamous cell carcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- PRISM-xQTL: Pleiotropic Relationships Integrated with System-level Multiomic QTL analysis for causal genes and molecular mediators in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFCER1G as an immune-associated protein, which belongs to the immunoglobulin superfamily and is involved in mediating and executing antibody-mediated immune responses. However, the role of FCER1G in cancers remains controversial. Our objectives were to study the association between FCER1G and tumor- infiltrating immune cells (TIICs) as well as the predictive significance of FCER1G.
methodsThe expression of FCER1G and its prognostic value in ESCC was examined by The Cancer Genome Atlas and Gene Expression Omnibus databases. We also evaluated the relationship between FCER1G expression and 22 TIICs. Immunohistochemistry was used to detect the expression and distribution of FCER1G. Double immunofluorescence was used to detect the co-expression of FCER1G and CD163 positive cells. Kaplan-Meier survival curves and Cox regression analysis was performed to determine the prognostic significance of FCER1G and CD163.
resultsThe analysis revealed that FCER1G was upregulated in ESCC, which was distributed more in the intra-tumor mesenchyme than in the cancer nests. The more infiltration in intra-tumor mesenchyme the worse the overall survival (OS) for patients with ESCC. The infiltration of FCER1G
conclusionsFCER1G
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.